

Please type a plus sign (+) inside this box →



PTO/SB/81 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY OR
AUTHORIZATION OF AGENT**

Application Number	09/775,812
Filing Date	February 6, 2001
First Named Inventor	Robert M. Scarborough
Group Art Unit	1624
Examiner Name	Bruck Kifle
Attorney Docket Number	021390-0020300US

I hereby appoint:

☒ Practitioners at Customer Number
OR

20350

Place Customer
Number Bar Code
Label here☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☒ The above-mentioned Customer Number.
OR☐ Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Certificate under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name	Robert Silverman
Signature	<i>Robert Silverman</i>
Date	JULY 29, 2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ *Total of 1 form is submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/98 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No. 021390-0020300

Cll nt R f. No.MPI00-696P1RN

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Robert M. Scarborough, Hans-Michael Jantzen, Wolin Huang, David M. Sedlock and Charles Marlow

Application No./Patent No.: 09/775,812

Filed/Issue Date: February 5, 2001

Entitled: PLATELET ADP RECEPTOR INHIBITORS

Millennium Pharmaceuticals, Inc.

a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

In the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Robert M. Scarborough, Hans-Michael Jantzen, Wolin Huang, David M. Sedlock and Charles Marlow To: Cor Therapeutics, Inc.

The document was recorded in the United States Patent and Trademark Office at Reel 011716, Frame 0740, or for which a copy thereof is attached.

2. Merger of: Cor Therapeutics, Inc. Into: Millennium Pharmaceuticals, Inc.
A copy of the Certificate of Merger is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.6)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

JULY 29, 2002

Date

Robert Silverman

Typed or printed name

Robert Silverman


Signature

Sr. Patent Counsel

Title


Commonwealth of Massachusetts)
)ss.
County of Middlesex)

I, Joel S. Goldberg, hereby swear that the attached reproduction of the Certificate of Merger of PGM Corporation (a Delaware corporation) into COR Therapeutics, Inc. (a Delaware corporation) dated February 12, 2002, is a true, correct and complete photocopy of a document in my possession.



Joel S. Goldberg
Counsel
Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, Massachusetts 02139

Subscribed and sworn to before me this 14th day of May, 2002 by Joel S. Goldberg.



Jean L. Ernst
Notary Public
My commission expires: August 15, 2008

(Seal)

CERTIFICATE OF MERGER

OF

PGM CORPORATION
(a Delaware corporation)

INTO

COR THERAPEUTICS, INC.
(a Delaware corporation)

COR Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify:

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger is as follows:

<u>Name</u>	<u>State of Incorporation</u>
PGM Corporation	Delaware
COR Therapeutics, Inc.	Delaware

SECOND: That an Agreement and Plan of Merger, dated December 5, 2001, by and among Millennium Pharmaceuticals, Inc., a Delaware corporation, PGM Corporation and COR Therapeutics, Inc. setting forth the terms and conditions of the merger of PGM Corporation with and into COR Therapeutics, Inc. has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of Subsection (c) of Section 251 of the General Corporation Law of the State of Delaware.

THIRD: That the name of the surviving corporation of the merger is COR Therapeutics, Inc.

FOURTH: That the Restated Certificate of Incorporation of COR Therapeutics, Inc., a Delaware corporation which will survive the merger, shall be the Restated Certificate of Incorporation of the surviving corporation, and shall be amended so that Article FOURTH of such Restated Certificate of Incorporation reads in its entirety as follows:

“FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is 1,000, all of which shall consist of common stock, \$.01 par value per share.”

FIFTH: That the executed Agreement and Plan of Merger is on file at the principal place of business of the surviving corporation. The address of said principal place of business is COR Therapeutics, Inc., 256 E. Grand Avenue, South San Francisco, California, 94080.


SIXTH: That a copy of the Agreement and Plan of Merger will be furnished by the surviving corporation upon request and without cost to any stockholder of any constituent corporation.

SEVENTH: That this Certificate of Merger shall be effective as of 4:01 p.m. Eastern Standard Time on February 12, 2002.

IN WITNESS WHEREOF, COR Therapeutics, Inc. has caused this Certificate to be executed by its President and Chief Executive Officer and attested by its Secretary this 12th day of February, 2002.


COR THERAPEUTICS, INC.

(a Delaware corporation)

By: 
Vaughn M. Kailian
President and
Chief Executive Officer

Dated: February 12, 2002

ATTEST:


Patrick A. Broderick
Secretary

086

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

ATTORNEY DOCKET NO.: 044481-5060

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PLATELET ADP RECEPTOR INHIBITORS

the specification of which:

is attached hereto; or

was filed as United States application Serial No. _____ on February 5, 2001 and was amended on _____ (if applicable); or

was filed as PCT international application Number _____ on _____ and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby authorize and request the attorneys empowered in this Declaration and Power of Attorney to insert above the serial number of the application identified above when known.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN APPLICATION(S):

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.: 044481-5060

I hereby claim the benefits under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

U.S. PROVISIONAL APPLICATIONS

U.S. PROVISIONAL APPLICATION NO.	U.S. FILING DATE
60/180,208	February 4, 2000
60/202,072	May 5, 2000
60/230,447	September 6, 2000

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT:

U.S. APPLICATIONS		STATUS (Check One)		
U.S. APPLICATION NO.	U.S. FILING DATE	PATENTED	PENDING	ABANDONED




POWER OF ATTORNEY: As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 009629

Direct Telephone Calls To:
(name and telephone number)

Reid G. Adler
202-467-7756

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF FIRST INVENTOR	Robert M. SCARBOROUGH	
RESIDENCE & CITIZENSHIP	Half Moon Bay, CA	COUNTRY OF CITIZENSHIP USA
POST OFFICE ADDRESS	22 Greenbrier Court Half Moon Bay, CA 94019	
FIRST INVENTOR'S SIGNATURE		DATE 2-26-01
FULL NAME OF SECOND INVENTOR	Hans-Michael JANTZEN	
RESIDENCE & CITIZENSHIP	San Francisco, CA	COUNTRY OF CITIZENSHIP USA
POST OFFICE ADDRESS	350 Church Street, #H San Francisco, CA 94114	
SECOND INVENTOR'S SIGNATURE		DATE 3-7-01
FULL NAME OF THIRD INVENTOR	Wolin HUANG	
RESIDENCE & CITIZENSHIP	Foster City, CA	COUNTRY OF CITIZENSHIP USA
POST OFFICE ADDRESS	872 Arcturus Circle Foster City, CA 94404	
THIRD INVENTOR'S SIGNATURE		DATE 2-27-01

Listing of Inventors Continued on attached page(s) ☒ Yes ☐ No

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.: 044481-5060

FULL NAME OF FOURTH INVENTOR	David M. SEDLOCK	
RESIDENCE & CITIZENSHIP	Burlingame, CA	COUNTRY OF CITIZENSHIP USA
POST OFFICE ADDRESS	2344 Poppy Drive Burlingame, CA 94010	
FOURTH INVENTOR'S SIGNATURE <i>David M. Sedlock</i>		DATE 2/27/01
FULL NAME OF FIFTH INVENTOR	Charles MARLOWE	
RESIDENCE & CITIZENSHIP	Redwood City, CA	COUNTRY OF CITIZENSHIP USA
POST OFFICE ADDRESS	636 California Way Redwood City, CA 94080	
FIFTH INVENTOR'S SIGNATURE <i>Charles Marlowe</i>		DATE 2/27/01
FULL NAME OF SIXTH INVENTOR		
RESIDENCE & CITIZENSHIP		COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS		
SIXTH INVENTOR'S SIGNATURE		DATE
FULL NAME OF SEVENTH INVENTOR		
RESIDENCE & CITIZENSHIP		COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS		
SEVENTH INVENTOR'S SIGNATURE		DATE

Listing of Inventors Continued on attached page(s) [] Yes [X] No



UNITED STATES
PATENT AND
TRADEMARK OFFICE

21390-00203045

MST
PATSL

AUGUST 13, 2002

PTAS

Chief Information Officer
Washington, DC 20231
www.uspto.gov

MORGAN, LEWIS & BOCKIUS LLP
MICHAEL S. TUSCAN P.H.
1111 PENNSYLVANIA AVE., NW
WASHINGTON, D.C. 20004



102122836A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/10/2002

REEL/FRAME: 012977/0516
NUMBER OF PAGES: 7

BRIEF: MERGER (SEE DOCUMENT FOR DETAILS):

ASSIGNOR:

COR THERAPEUTICS, INC.

DOC DATE: 02/12/2002

ASSIGNEE:

MILLENNIUM PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 07808329 44481-5002-01
PATENT NUMBER:

FILING DATE: 12/16/1991
ISSUE DATE:

mst/mst/RJS
Abandoned

SERIAL NUMBER: 08477133 44481-5002-06
PATENT NUMBER:

FILING DATE: 06/07/1995
ISSUE DATE:

mst/mst/RJS
Lapsed

SERIAL NUMBER: 093622074 4481-5002-14
PATENT NUMBER:

FILING DATE: 07/28/1999
ISSUE DATE:

mst/mst/RJS
Abandoned

SERIAL NUMBER: 09671346 44481-5002-15
PATENT NUMBER:

FILING DATE: 09/27/2000
ISSUE DATE:

mst/mst/RJS

RECORDED

AUG 19 2002

MORGAN, LEWIS & BOCKIUS LLP

DOCKETED

By SAW Date 9-11-02

SERIAL NUMBER: 07854109-44481-5004
PATENT NUMBER:

FILING DATE: 03/20/1992 MST/MST/RJS
ISSUE DATE:

SERIAL NUMBER: 08475262-44481-5004-02
PATENT NUMBER:

FILING DATE: 06/07/1995 MST/MST/RJS
ISSUE DATE:

SERIAL NUMBER: 09621004-44481-5004-04
PATENT NUMBER:

FILING DATE: 07/20/2000 MST/MST/RJS
ISSUE DATE:

SERIAL NUMBER: 08390301-44481-5006-01
PATENT NUMBER:

FILING DATE: 01/25/1995 MST/MST/RK
ISSUE DATE: Abandoned

SERIAL NUMBER: 08474414-44481-5006-02
PATENT NUMBER:

FILING DATE: 06/07/1995 MST/MST/RK
ISSUE DATE: Abandoned

SERIAL NUMBER: 08486673-44481-5006-06
PATENT NUMBER: 6297026

FILING DATE: 06/07/1995 MST/MST/RK
ISSUE DATE: 10/02/2001 C/osed

SERIAL NUMBER: 10127691-44481-5006-09
PATENT NUMBER:

FILING DATE: 04/23/2002 MST/MST/RK
ISSUE DATE:

SERIAL NUMBER: 09035135-44481-5007-04
PATENT NUMBER:

FILING DATE: 03/05/1998 MST/ECW/RK
ISSUE DATE: Abandoned

SERIAL NUMBER: 09801089-44481-5008-02
PATENT NUMBER:

FILING DATE: 03/08/2001 MST/MST/RJS
ISSUE DATE:

SERIAL NUMBER: 09410738-44481-5010-02
PATENT NUMBER:

FILING DATE: 10/01/1999 MST/MST/RK
ISSUE DATE: Abandoned

SERIAL NUMBER: 09947922-44481-5010-03
PATENT NUMBER:

FILING DATE: 09/07/2001 MST/MST/RK
ISSUE DATE: Abandoned

SERIAL NUMBER: 07801795-44481-5017
PATENT NUMBER:

FILING DATE: 12/02/1991 MST/MST/RJS
ISSUE DATE: Abandoned

SERIAL NUMBER: 08253440-44481-5017-01
PATENT NUMBER:

FILING DATE: 06/07/1994 MST/MST/RJS
ISSUE DATE: Abandoned

SERIAL NUMBER: 09419076-44481-5017-07
PATENT NUMBER:

FILING DATE: 10/15/1999 MST/MST/RK
ISSUE DATE:

SERIAL NUMBER: 09585410-44481-5017-05
PATENT NUMBER:

FILING DATE: 06/02/2000 MST/MST/RK
ISSUE DATE:

SERIAL NUMBER: 08089455-44481-5018
PATENT NUMBER:

FILING DATE: 07/09/1993 MST/ECW/RJS
ISSUE DATE: Abandoned

SERIAL NUMBER: 08884571-44481-5018-03
PATENT NUMBER:

FILING DATE: 06/27/1997 MST/ECW/RJS
ISSUE DATE: Abandoned

SERIAL NUMBER: 09560814-44481-5018-04
PATENT NUMBER:

FILING DATE: 04/28/2000 MST/ECW/RK
ISSUE DATE:

SERIAL NUMBER: 09991888	44481-5025-03	FILING DATE: 11/26/2001	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09473716	44481-5027-01	FILING DATE: 12/29/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09474076	44481-5028-01	FILING DATE: 12/29/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 10071223	44481-5029-02	FILING DATE: 02/11/2002	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08975653	44481-5039-02	FILING DATE: 11/21/1997	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09673302	44481-5043	FILING DATE: 03/23/2001	MST/ECW/SEZ
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09775803	44481-5044-01	FILING DATE: 02/05/2001	MST/ECW/SEZ
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09745842	44481-5053	FILING DATE: 12/26/2000	MST/MST/EDL
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08948672	44481-5012	FILING DATE: 10/10/1997	
PATENT NUMBER: 6262047		ISSUE DATE: 07/17/2001	Transfer to T+T+C
SERIAL NUMBER: 09500231	44481-5015	FILING DATE: 02/08/2000	
PATENT NUMBER:		ISSUE DATE:	Transfer to T+T+C
SERIAL NUMBER: 09664535	44481-5041-99	FILING DATE: 09/18/2000	JAL/ECW/ECW
PATENT NUMBER:		ISSUE DATE:	ABANDONED
SERIAL NUMBER: 09663420	44481-5061	FILING DATE: 09/15/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 10126976	44481-5061-02	FILING DATE: 04/22/2002	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09226103	44481-5042	FILING DATE: 01/07/1999	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09501370	44481-5045	FILING DATE: 02/11/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09501371	44481-5045-01	FILING DATE: 02/11/2000	
PATENT NUMBER: 6399627		ISSUE DATE: 06/04/2002	Transferred to T+T+C
SERIAL NUMBER: 09576637	44481-5046	FILING DATE: 05/24/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09576634	44481-5046-01	FILING DATE: 05/24/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C

SERIAL NUMBER: 09576638 44481-5047
 PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09577131 44481-5047-01
 PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576635 44481-5048
 PATENT NUMBER:

FILING DATE: 05/20/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576636 44481-5048-01
 PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576633 44481-5049
 PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576632 44481-5049-01
 PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09577154 44481-5049-02
 PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09636804 44481-5050
 PATENT NUMBER:

FILING DATE: 08/10/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09662807 44481-5051
 PATENT NUMBER:

FILING DATE: 09/15/2000 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09794214 44481-5051-01
 PATENT NUMBER:

FILING DATE: 02/28/2001 Transferred
 ISSUE DATE: to T+T+C

SERIAL NUMBER: 09714532 44481-5052
 PATENT NUMBER:

FILING DATE: 11/17/2000 Transferred to
 ISSUE DATE: T+T+C

SERIAL NUMBER: 09773383 44481-5055
 PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to
 ISSUE DATE: T+T+C

SERIAL NUMBER: 09773372 44481-5056
 PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to
 ISSUE DATE: T+T+C

SERIAL NUMBER: 09773373 44481-5057
 PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to
 ISSUE DATE: T+T+C

SERIAL NUMBER: 09773374 44481-5058
 PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to
 ISSUE DATE: T+T+C

SERIAL NUMBER: 09773375 44481-5059
 PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to
 ISSUE DATE: T+T+C

SERIAL NUMBER: 09775812 44481-5060
 PATENT NUMBER:

FILING DATE: 02/05/2001 Transferred to
 ISSUE DATE: T+T+C

SERIAL NUMBER: 09920325 44481-5060-01
 PATENT NUMBER:

FILING DATE: 08/02/2001 Transferred to
 ISSUE DATE: T+T+C

012977/0516 PAGE 5

SERIAL NUMBER: 09816782 44481-5062
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred
ISSUE DATE: TO T+TC

SERIAL NUMBER: 09816771 44481-5063
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred to
ISSUE DATE: T+TC

SERIAL NUMBER: 09816781 44481-5064
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred +
ISSUE DATE: T+TC

TARA WASHINGTON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

FORM PTO-1595
(Rev. 6-93)



06-14-2002



102122836

RECORDATION FORM COVER SHEET
PATENTS ONLY

MENT OF COMMERCE
ent and Trademark Office

Attorney Docket No.: 44481-0021-US

To the Assistant Commissioner for Patents:
Please record the attached original documents or copy thereof.

ATTN: BOX ASSIGNMENT

1. Name of conveying party(ies):

COR Therapeutics, Inc.

6-10-02

Additional name(s) of conveying party(ies) attached?

Yes ☒ No

2. Name and address of receiving party(ies):

Name: Millennium Pharmaceuticals, Inc.

Street Address: 75 Sidney Street

City: Cambridge State: MA

Country: US Zip: 02139

3. Nature of conveyance:

☐ Assignment ☒ Merger
☐ Security Agreement ☐ Change of Name
☐ Other _____

Additional name(s) & address(es) attached?

Yes ☒ No

Execution Date(s): February 12, 2002

4. Application number(s) or patent number(s):

If this document is being filed together with a new application the execution date of the application is:

A. Patent Application No.(s): 07/808,329

B. Patent No.(s)

Additional numbers attached: ☒ Yes ☐ No See attached Schedule B.

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Michael S. Tuscan, Ph.D.
Internal Address: Customer No. 009629
Morgan, Lewis & Bockius LLP

Street Address: 1111 Pennsylvania Ave., NW
City: Washington State: D.C. Zip: 20004

6. Total number of applications and patents involved: 61

7. Total fee (37 C.F.R. §3.41): \$2440.00

☐ Enclosed

☒ Authorized to be charged to deposit account 50-0310

8. Deposit account number: 50-0310

Attach duplicate of page if paying by deposit account

9. Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Michael S. Tuscan, Ph.D., Reg. No. 43,210

Name of Person Signing

Michael S. Tuscan
Signature

June 10, 2002
Date

06/13/2002 DBYRNE 00000040 500310 07808329

Total number of pages including cover sheet, attachments and documents: 8

01 FC1581

2440.00 CH

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
07/808,329	1991-12-16	Antithrombosis agents	44481-5002-01
08/477,133	1995-06-07	Agents affecting thrombosis and hemostasis	44481-5002-06
09/362,207	1999-07-28	Agents affecting thrombosis and hemostasis	44481-5002-14
09/671,346	2000-09-27	Agents affecting thrombosis and hemostasis	44481-5002-15
07/854,109	1992-03-20	Glycosylation-mediated inhibition of Factor X	44481-5004
08/475,262	1995-06-07	Glycosylation-mediated inhibition of Factor X	44481-5004-02
09/621,004	2000-07-20	Glycosylation-mediated inhibition of Factor X	44481-5004-04
08/390,301	1995-01-25	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-01
08/474,414	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-02
08/486,673	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-06
10/127,691	2002-04-23	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-09
09/035,135	1998-03-05	Process for production of inhibited forms of activated blood factors	44481-5007-04
09/801,089	2001-03-08	Modulation of integrin-mediated signal transduction	44481-5008-02
09/410,738	1999-10-01	Methods of screening for compounds that interact with human P _{2U2} purinergic receptor	44481-5010-02
09/947,922	2001-09-07	Methods of screening for compounds that interact with human P _{2U2} purinergic receptor	44481-5010-03
07/801,795	1991-12-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017
08/253,440	1994-06-07	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-01
09/419,076	1999-10-15	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-04
09/585,410	2000-06-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-05
08/089,455	1993-07-09	Platelet glycoprotein V gene and uses	44481-5018
08/884,571	1997-06-27	Platelet glycoprotein V gene and uses	44481-5018-03
09/560,814	2000-04-28	Platelet glycoprotein V gene and uses	44481-5018-04

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/991,888	2001-11-26	Identification of Bap-1, a protein that binds to integrin and is Involved in integrin-mediated signal transduction	44481-5025-03
09/473,716	1999-12-29	Polynucleotides encoding a type V adenylyl cyclase	44481-5027-01
09/474,076	1999-12-29	Cloning and characterization of a human adenylyl cyclase	44481-5028-01
10/071,223	2002-02-11	Cloning and characterization of a human adenylyl cyclase	44481-5029-02
08/975,653	1997-11-21	Modulation of interactions between myosin and integrins	44481-5039-01
09/673,302	2001-03-23	Transgenic mammals expressing mutant GP IIIa	44481-5043
09/775,803	2001-02-05	Transgenic animals having a modified glycoprotein V gene	44481-5044
09/745,842	2000-12-26	P ₂ Y ₁₂ receptor	44481-5053
08/948,672	1997-10-10	Selective Factor Xa inhibitors	44481-5012-01
09/500,231	2000-02-08	Selective Factor Xa inhibitors	44481-5015-02
09/664,535	2000-09-18	Benzamides and related inhibitors of Factor Xa	44481-5061-99
09/663,420	2000-09-15	Benzamides and related inhibitors of Factor Xa	44481-5061
10/126,976	2002-04-22	Benzamides and related inhibitors of Factor Xa	44481-5061-02
09/226,103	1999-01-07	Platelet ADP receptor inhibitors	44481-5042
09/501,370	2000-02-11	Alkenyl and alkynyl compounds as inhibitors of Factor Xa	44481-5045
09/501,371	2000-02-11	Inhibitors of Factor Xa	44481-5045-01
09/576,637	2000-05-24	Inhibitors of Factor Xa	44481-5046
09/576,634	2000-05-24	Inhibitors of Factor Xa	44481-5046-01
09/576,638	2000-05-24	Inhibitors of Factor Xa	44481-5047
09/577,131	2000-05-24	Inhibitors of Factor Xa	44481-5047-01
09/576,635	2000-05-24	Inhibitors of Factor Xa	44481-5048
09/576,636	2000-05-24	Inhibitors of Factor Xa	44481-5048-01
09/576,633	2000-05-24	Inhibitors of Factor Xa	44481-5049
09/576,632	2000-05-24	Inhibitors of Factor Xa	44481-5049-01
09/577,154	2000-05-24	Inhibitors of Factor Xa	44481-5049-02
09/636,804	2000-08-10	Inhibitors of Factor Xa	44481-5050

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/662,807	2000-09-15	Inhibitors of Factor Xa	44481-5051
09/794,214	2001-02-28	Inhibitors of Factor Xa	44481-5051-01
09/714,532	2000-11-17	β -Amino acid-, aspartic acid- and diaminopropionic -based inhibitors of Factor Xa	44481-5052
09/773,383	2001-02-01	Indole and benzimidazole inhibitors of Factor Xa	44481-5055
09/773,372	2001-02-01	Indalone and benzimidazolone inhibitors of Factor Xa	44481-5056
09/773,373	2001-02-01	3,4-Dihydro-2h-benzo[1,4]oxazine inhibitors of Factor Xa	44481-5057
09/773,374	2001-02-01	2-[1H]-Quinolone and 2-[1H]-quinoxalone inhibitors of Factor Xa	44481-5058
09/773,375	2001-02-01	Bivalent phenylene inhibitors of Factor Xa	44481-5059
09/775,812	2001-02-05	Platelet ADP receptor inhibitors	44481-5060
09/920,325	2001-08-02	Platelet ADP receptor inhibitors	44481-5060-01
09/816,782	2001-03-26	Oxindole inhibitors of Factor Xa	44481-5062
09/816,771	2001-03-26	Isoquinolone inhibitors of Factor Xa	44481-5063
09/816,781	2001-03-26	Bicyclic sulfonyl amino inhibitors of Factor Xa	44481-5064

Delaware

PAGE 1


The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"COR THERAPEUTICS, INC.", A DELAWARE CORPORATION,

WITH AND INTO "MILLENNIUM PHARMACEUTICALS, INC." UNDER THE NAME OF "MILLENNIUM PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWELFTH DAY OF FEBRUARY, A.D. 2002, AT 6 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

2322355 8100M

AUTHENTICATION: 1610075

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

COR THERAPEUTICS, INC.
(a Delaware corporation)

INTO

MILLENNIUM PHARMACEUTICALS, INC.
(a Delaware corporation)

Millennium Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify:

FIRST: That the Corporation was incorporated on the 13th day of January, 1993, pursuant to the General Corporation Law of the State of Delaware.

SECOND: That the Corporation owns all of the outstanding shares of each class of the stock of COR Therapeutics, Inc., a corporation incorporated on the 4th day of February, 1988 pursuant to the General Corporation Law of the State of Delaware.

THIRD: That the Board of Directors of the Corporation, by written action in lieu of a meeting dated the 4th day of February, 2002, duly adopted the following resolutions:

RESOLVED: That, pursuant to Section 253 of the Delaware General Corporation Law, the Corporation is hereby authorized to merge COR Therapeutics, Inc., a Delaware corporation which is a wholly owned subsidiary of the Corporation, into the Corporation;

RESOLVED: That the President and Secretary of the Corporation be, and each of them hereby is, authorized to execute a Certificate of Ownership and Merger with respect to the merger of COR Therapeutics, Inc. into the Corporation, cause the same to be filed with the Secretary of State of the State of Delaware and take all such other actions and to execute all such other instruments and agreements as the officer or officers so acting may deem appropriate to effect such merger;

RESOLVED: That the merger of COR Therapeutics, Inc. into the Corporation shall be effective upon the filing of a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its authorized officer this 12th day of February, 2002:

MILLENNIUM
PHARMACEUTICALS, INC.

By: /s/ Mark J. Levin
Title: President



UNITED STATES
PATENT AND
TRADEMARK OFFICE

OCTOBER 17, 2002

TOWNSEND AND TOWNSEND AND CREW LLP
WILLIAM B. KEZER
TWO EMBARCADERO CENTER, 8TH FLOOR
SAN FRANCISCO, CA 94111-3834

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov



102188024A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/06/2002

REEL/FRAME: 013173/0689
NUMBER OF PAGES: 4

BRIEF: MERGER (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

COR THERAPEUTICS, INC.

DOC DATE: 02/12/2002


ASSIGNEE:

MILLENNIUM PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 09775812
PATENT NUMBER:

FILING DATE: 02/05/2001
ISSUE DATE:

MARY BENTON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



8/6/02

Attorney Docket No. 021390-002030US


Form PTO-155 (Rev. 03-01) OMB No. 0651-0027 (exp. 5/31/2002)		U.S. Department of Commerce U.S. Patent and Trademark Office	
Tab settings < < <		08-13-2002	
To the Honorable Commissioner		attached original documents or copy thereof	
1. Name of conveying party(ies): COR Therapeutics, Inc.		102188024 Name: Millennium Pharmaceuticals, Inc.	
Additional name(s) of conveying parties attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No.		Internal Address: _____	
3. Nature of conveyance: <input type="checkbox"/> Assignment <input checked="" type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: _____		Street Address: 75 Sidney Street City: Cambridge State: MA ZIP: 02139	
Execution Date: February 12, 2002		Additional names and addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
4. Application number(s) or patent number(s). If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No(s): 09/775,812 B. Patent No(s): _____ Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
5. Name and address of party to whom correspondence concerning document should be mailed: Name: William B. Kezer TOWNSEND AND TOWNSEND AND CREW LLP Two Embarcadero Center, 8 th Floor San Francisco, California 94111-3834 (415) 576-0200		6. Total number of applications and patents involved 1 7. Total fee (37 CFR 3.41): -----\$40.00 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account 8. Deposit account number: 20-1430 (Attach duplicate copy of this page if paying by deposit account)	
DO NOT USE THIS SPACE			
9. Statement and signature. To the best of my knowledge and belief, the foregoing is true and correct and any attached copy is a true of copy of the original document. William B. Kezer Name of Person Signing Atty. Reg. No. 37,369 [Signature] Signature 8.1.02 Date			
Total number of pages including cover sheet, attachments and document 4			

Mail documents to be recorded with required cover t :
Commissioner of Patents and Trademarks, Box Assignments
Washington, D.C. 20231

08/12/2002 DBYRNE 00000091 201430 09775812
01 FC:581 40.00 CH


Commonwealth of Massachusetts)
)ss.
County of Middlesex)

I, Joel S. Goldberg, hereby swear that the attached reproduction of the Certificate of Merger of PGM Corporation (a Delaware corporation) into COR Therapeutics, Inc. (a Delaware corporation) dated February 12, 2002, is a true, correct and complete photocopy of a document in my possession.



Joel S. Goldberg
Counsel
Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, Massachusetts 02139

Subscribed and sworn to before me this 14th day of May, 2002 by Joel S. Goldberg.



Jean L. Ernst
Notary Public
My commission expires: August 15, 2008

(Seal)



CERTIFICATE OF MERGER

OF

PGM CORPORATION
(a Delaware corporation)

INTO

COR THERAPEUTICS, INC.
(a Delaware corporation)

COR Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify:

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger is as follows:

Name

State of Incorporation

PGM Corporation
COR Therapeutics, Inc.

Delaware
Delaware

SECOND: That an Agreement and Plan of Merger, dated December 5, 2001, by and among Millennium Pharmaceuticals, Inc., a Delaware corporation, PGM Corporation and COR Therapeutics, Inc. setting forth the terms and conditions of the merger of PGM Corporation with and into COR Therapeutics, Inc. has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of Subsection (c) of Section 251 of the General Corporation Law of the State of Delaware.

THIRD: That the name of the surviving corporation of the merger is COR Therapeutics, Inc.

FOURTH: That the Restated Certificate of Incorporation of COR Therapeutics, Inc., a Delaware corporation which will survive the merger, shall be the Restated Certificate of Incorporation of the surviving corporation, and shall be amended so that Article FOURTH of such Restated Certificate of Incorporation reads in its entirety as follows:

“FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is 1,000, all of which shall consist of common stock, \$.01 par value per share.”

FIFTH: That the executed Agreement and Plan of Merger is on file at the principal place of business of the surviving corporation. The address of said principal place of business is COR Therapeutics, Inc., 256 E. Grand Avenue, South San Francisco, California, 94080.

SIXTH: That a copy of the Agreement and Plan of Merger will be furnished by the surviving corporation upon request and without cost to any stockholder of any constituent corporation.

SEVENTH: That this Certificate of Merger shall be effective as of 4:01 p.m. Eastern Standard Time on February 12, 2002.

IN WITNESS WHEREOF, COR Therapeutics, Inc. has caused this Certificate to be executed by its President and Chief Executive Officer and attested by its Secretary this 12th day of February, 2002.

COR THERAPEUTICS, INC.

(a Delaware corporation)

By:




Vaughn M. Kailian

President and

Chief Executive Officer

Dated: February 12, 2002

ATTEST:



Patrick A. Broderick

Secretary



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

EC
EC
DK

JULY 06, 2001

MORGAN, LEWIS & BOCKIUS LLP
ELIZABETH C. WEIMAR
1800 M STREET, N.W.
WASHINGTON, D.C. 20036

PTAS RECEIVED



101692423A

JUL 10 2001

MORGAN, LEWIS & BOCKIUS LI

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 04/20/2001

REEL/FRAME: 011716/0740
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

SCARBOROUGH, ROBERT M.

DOC DATE: 02/26/2001

ASSIGNOR:

JANTZEN, HANS-MICHAEL

DOC DATE: 03/07/2001

ASSIGNOR:

HUANG, WOLIN

DOC DATE: 02/27/2001

ASSIGNOR:

SEDLOCK, DAVID M.

DOC DATE: 02/27/2001

ASSIGNOR:

MARLOWE, CHARLES

DOC DATE: 02/27/2001

ASSIGNEE:

COR THERAPEUTICS, INC.
256 EAST GRAND AVE.
SOUTH SAN FRANCISCO, CALIFORNIA

94080

44481-5060
DOCKETED
By SW Date 7-10-01

011716/0740 PAGE 2

SERIAL NUMBER: 09775812
PATENT NUMBER:

FILING DATE: 02/05/2001
ISSUE DATE:

SAUNDRA BALLENGER, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



RECORDATION FORM COVER SHEET
PATENTS ONLY

04-27-2001



101692423

Attorney Docket No.: 044481-5060

To the Assistant Commissioner for Patents:

Please record the attached original documents or copy thereof.

ATTN: BOX ASSIGNMENT

1. Name of conveying party(ies):

- (i) Robert M. Scarborough
- (ii) Hans-Michael Jantzen
- (iii) Wolin Huang
- (iv) David M. Sedlock
- (v) Charles Marlowe

Additional name(s) of conveying party(ies) attached?

2. Name and address of receiving party(ies):

Name: COR Therapeutics, Inc.

Internal Address:

Street Address: 256 East Grand Ave,
South San Francisco, CA 94080

City:

State:

Zip:

Additional name(s) & address(es) attached?

☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
- ☐ Security Agreement ☐ Change of Name
- ☐ Other

Execution Date: (i) February 26, 2001, (ii) March 7, 2001, (iii)
February 27, 2001, (iv) February 27, 2001 and (v) February 27, 2001

4. Application number(s) or patent number(s):

If this document is being filed together with a new application the execution date of the application is:

A. Patent Application No.(s): 09/775,812

B. Patent No.(s)

Additional numbers attached: ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Elizabeth C. Weimar

Internal Address: Customer No. 009629
Morgan, Lewis & Bockius LLP

Street Address: 1800 M Street, N.W.
City: Washington State: D.C. Zip: 20036

6. Total number of applications and patents involved: 1

7. Total fee (37 C.F.R. §3.41): \$40.00

☒ Enclosed

☐ Authorized to be charged to deposit account 50-0310

8. Deposit account number: 50-0310

Attach duplicate of page if paying by deposit account

9. Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Elizabeth C. Weimar
Name of Person Signing
Reg. No. 44,478

Jeffrey A. Lindeman
Reg No 34,658
Signature

April 20, 2001
Date

Total number of pages including cover sheet, attachments and documents: 3

04/26/2001 6TON11 00000320 09775812

01 FC:581

40.00 OP

ASSIGNMENT

WHEREAS I/We, a below named inventor(s), [hereinafter referred to as Assignor(s)], have made an invention entitled:

PLATELET ADP RECEPTOR INHIBITORS

for which I/WE executed an application for United States Letters Patent concurrently herewith; or on February 5, 2001; or filed a provisional application for United States Letters Patent on _____, (Serial No. _____); and

WHEREAS, COR Therapeutics, Inc., a corporation of California, whose post office address is 256 E. Grand Avenue, South San Francisco, CA 94080 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;


NOW THEREFORE, be it known that, for and in consideration of the sum of One Dollar (\$1.00) in hand paid and other good and valuable consideration the receipt of which from assignee is hereby acknowledged, I/WE, as assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the assignee, its lawful successors and assigns, MY/OUR entire right, title, and interest in and to this invention and this provisional application, any non-provisional application claiming benefit of the provisional application, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority on the basis of such application, and all applications for Letters Patent which may hereafter be filed for this invention in any foreign country and all Letters Patent which may be granted on this invention in any foreign country, and all extensions, renewals, and reissues thereof; and I/WE hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/WE have the full right to convey the interest assigned by this Assignment, and I/WE have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/WE will, without further consideration, communicate with assignee, its successors and assigns, any facts known to ME/US respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said assignee, its successors or assigns, execute all non-provisional, divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys of Morgan, Lewis & Bockius LLP, United States Patent and Trademark Office Customer No. 009629, to insert here in parentheses (Application No. _____, filed February 5, 2001) the filing date and application number of said application when known.

IN TESTIMONY WHEREOF, I/WE have hereunto set our hand(s).

County of _____ State of _____	SS.	<u>Robert M. Scarborough</u> Full Name of Sole or First Assignor
		<u>22 Greenbrier Court, Half Moon Bay, CA 94019</u> Address
Subscribed and sworn to before me this ____ day of _____, 2001.		<u></u> First Assignor's Signature
_____ Notary Public		<u>2-26-01</u> Date
Names of additional inventors attached [X] Yes [] No		

IN TESTIMONY WHEREOF, I/WE have hereunto set our hand(s).

County of _____ State of _____	SS.	<u>Hans-Michael Jantzen</u> Full Name Second Assignor <u>350 Church Street, #H, San Francisco, CA 94114</u> Address <u>X <i>Hans-Michael Jantzen</i></u> Second Assignor's Signature <u>X 3-7-01</u> Date
Subscribed and sworn to before me this ____ day of _____, 2001. _____ Notary Public		

County of _____ State of _____	SS.	<u>Wolin Huang</u> Full Name Third Assignor <u>872 Arcturus Circle, Foster City, CA 94404</u> Address <u><i>Wolin Huang</i></u> Third Assignor's Signature <u>2-27-2001</u> Date
Subscribed and sworn to before me this ____ day of _____, 2001. _____ Notary Public		

County of _____ State of _____	SS.	<u>David M. Sedlock</u> Full Name Fourth Assignor <u>2344 Poppy Drive, Burlingame, CA 94010</u> Address <u><i>David M. Sedlock</i></u> Fourth Assignor's Signature <u>2/27/01</u> Date
Subscribed and sworn to before me this ____ day of _____, 2001. _____ Notary Public		

County of _____ State of _____	SS.	<u>Charles Marlowe</u> Full Name Fifth Assignor <u>636 California Way, Redwood City, CA 94080</u> Address <u><i>Charles Marlowe</i></u> Fifth Assignor's Signature <u>2/27/01</u> Date
Subscribed and sworn to before me this ____ day of _____, 2001. _____ Notary Public		

Names of additional inventors attached [] Yes [X] No